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‘Blood transfusion is like marriage: it should not be entered 
upon lightly, unadvisedly or wantonly, or more often than is 
absolutely necessary.’1
Blood services have been at the forefront of raising awareness 
of the HIV pandemic. The emergence and recognition of HIV 
as a transfusion transmissible infection (TTI) in the early 
1980s had a profound impact on blood services worldwide. 
There has been concerted international effort, expending 
considerable resources, to prevent transmission of TTIs 
through blood products and to provide safe blood products 
for transfusion. One means of reducing the risk of TTIs and 
properly managing haematological symptoms, especially in 
immunocompromised individuals, is appropriate clinical use 
of blood. This is contingent upon an appreciation of the risks 
of unnecessary transfusion. Clinicians should consider non-
transfusion options such as haematinics in the management 
of anaemia. The decision to transfuse should be based on an 
individual patient’s co-morbid and clinical status, rather than 
on laboratory indices only. Specific and careful consideration of 
each patient is therefore required when HIV-related anaemia or 
associated conditions raise the possibility of transfusion.
There have been numerous requests from members of 
the Southern African HIV Clinicians Society for guidance 
and direction on blood transfusion in HIV-infected patients. 
While the role of blood transfusion in the management 
of haematological conditions such as anaemia and 
thrombocytopaenia does not differ substantially between HIV-
negative and HIV-positive patients, it is the authors’ experience 
that there is a general need to promote rational transfusion 
practice. The objective of this review is not to provide a novel 
approach to the management of haematological conditions; 
rather, it is intended to provide a practical and succinct review 
on the rational use of blood transfusion in the management of 
haematological abnormalities, focusing on conditions either 
unique to, or more frequently encountered in, HIV-infected 
patients. This review should be read in conjunction with 
published national and international clinical guidelines.
(For a review of the ethical and legal considerations of 
transfusion and HIV, with a specific focus on South Africa, 
please refer to Appendix 1.)
Cytopaenias in HIV
Clinically significant cytopaenias (anaemia, thrombocytopaenia, 
neutropaenia) are common in persons with HIV.2 Many factors 
may contribute to the development of cytopaenias in HIV, 
including the virus itself that can infect progenitor cells directly, 
cytokine effects, reticulin fibrosis, altered immune function 
with auto-antibody production, micro-nutrient deficiency 
(folate, vitamin B12, iron), co-infection with other agents both 
opportunistic (e.g. TB, mycobacterium avium complex (MAC), 
cytomegalovirus (CMV), Ebstein-Barr virus) and conventional 
(e.g. bacteria, parvovirus), bone marrow infiltration by 
malignancy, and anaemia of chronic disease. Numerous drugs 
used in the management of HIV – including anti-retroviral 
therapy (ART) (e.g. AZT) and prophylactic therapies (e.g. 
co-trimoxazole) both may cause and exacerbate cytopaenias 
in HIV. In addition, bone marrow suppression in HIV occurs 
due to the effect of cytokines as well as reduced erythropoietin 
production and function.3-5
The decision to transfuse a patient is a clinical decision 
that needs to be individualised, informed by the patient’s 
clinical status, the laboratory findings where available, and 
available resources. This decision may incorporate the patient’s 
socio-economic circumstances: a patient with borderline 
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decompensated anaemia, living in a remote 
area with poor access to follow-up care, might 
warrant transfusion; whilst the same patient 
might otherwise be managed conservatively in 
an urban setting with access to care.6 In general, 
indications for transfusion in HIV-positive 
patients are the same as for HIV-negative 
patients. HIV-positive patients may, however, 
have compromised bone marrow function 
and require additional haematological support 
until such time that ART results in improved 
bone marrow function.
Bone marrow involvement
Bone marrow infiltration can result in anaemia 
through destruction of the haematopoietic 
environment. Infiltration is reflected by 
pancytopaenia and a reticulocyte production 
index (RPI) <1% and sometimes by a leuco-
erythroblastic reaction where immature red and 
white blood cells are visible on the peripheral 
blood smear. Ideally, evidence of a leuco-
erythroblastic reaction requires consideration 
of a bone marrow biopsy and specialist input. 
Common infiltrative processes in the setting 
of HIV include granulomatous infection (e.g. 
mycobacterial and fungal), lymphoproliferative 
disorders and fibrosis. Management will be 
determined by the underlying cause, with 
transfusion limited to patients who are 
symptomatic.
Dysplastic changes in the bone marrow 
are common, and may occur at any stage 
of HIV infection. Where available, bone 
marrow biopsy may be informative in 
investigating various diagnoses e.g. neoplasia 
(lymphoproliferative or myeloproliferative 
disorder) and opportunistic infections such 
as TB. Special stains and cultures for fungi, 
viruses and mycobacteria may help to resolve 
the cause of unexplained fever or source of 
infection.7 Although the same indications for 
bone marrow biopsy apply independently 
of HIV status, certain indications (e.g. 
pancytopaenia, pyrexia of unknown origin 
(PUO), and lymphadenopathy) feature more 
prominently in patients with HIV. Similarly, 
certain diagnoses are more prevalent in the HIV 
population (e.g. immune thrombocytopaenia, 
disseminated mycobacterial infection, 
disseminated fungal infection).
A bone marrow biopsy is an invasive 
procedure; it may be painful and is not without 
risk. The latter includes infection, bleeding 
and haematoma. It should not be a first step 
in investigation and, regarding haematological 
disorders, should ideally be accompanied, 
where available, by additional testing i.e. 
bone marrow aspiration, cytogenetics and 
immunophenotyping (e.g. flow cytometry) to 
provide maximal diagnostic yield. Availability 
of this testing is often confined to tertiary 
academic and private referral laboratories. 
Bone marrow investigations may be helpful in 
the following situations:
•	 bone marrow failure (pancytopaenia and 
reticulocyte production index (RPI) <1%)
•	 cytopaenias unresponsive to treatment
•	 investigation of opportunistic infection
•	 pyrexia of unknown origin (PUO) after 
initial investigations fail to identify the cause
•	 exclusion/staging of malignancy
•	 diagnosis of specific pathology, such as pure 
red cell aplasia
•	 atypical and/or abnormal blood cells noted 
in the peripheral blood smear.
Specimen adequacy is important for 
identifying a focal process (e.g. granuloma, 
metastatic carcinoma or lymphoid infiltrate). 
Both the focal nature of the pathology and 
increased marrow fibrosis (a component of 
granuloma formation) increases the risk of a 
non-diagnostic specimen.
Anaemia
Anaemia is not a diagnosis, and management 
should focus on investigation and treatment 
of the underlying cause, independent of HIV 
status. Anaemia refers to a reduced red cell 
mass as reflected by a decreased haematocrit 
or haemoglobin level. It is a clinical sign 
that reflects an underlying disease process 
that requires appropriate investigation and 
management that is specific to the underlying 
process. Anaemia is common to a diverse array 
of pathologies with similarly broad therapeutic 
options. Consequently, generic treatment (e.g. 
blood transfusion or haematinics) without 
knowledge of the specific cause is considered 
bad practice. As an example, iron-deficiency 
anaemia can be due to dietary deficiency 
(a simple problem of insufficient intake). 
However, it can also be due to chronic blood 
loss (e.g. menorrhagia, helminth infestation, 
visceral malignancy). Simply treating with 
iron supplements without a root-cause 
analysis ignores the differential diagnosis and 
may delay time-sensitive treatment of the 
actual cause (e.g. colonic carcinoma).
Table 1. Anaemia and HIV-infection
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Anaemia may occur at any stage of HIV 
infection, and 63 - 95% of infected persons 
will develop anaemia during the course of 
their illness; furthermore, the incidence of 
anaemia increases with disease progression.2 
The presence of anaemia is an independent, 
yet reversible, predictor of mortality.6,8,9 
Table 1 lists some of the causes of anaemia 
in HIV; it is by no means complete. The 
main aetiologies for HIV-related anaemia 
are dyserythropoiesis (anaemia of chronic 
disease), infections and drugs.2-5 In addition, 
anaemia may be compounded by co-morbid 
haematinic deficiency (iron, folate and 
vitamin B12), suggesting a need for early 
replacement in the management of anaemia in 
HIV. Zidovudine (AZT), especially when used 
as a single agent, is the drug historically most 
frequently implicated in HIV-related anaemia; 
a dose-dependent macrocytic anaemia is 
characteristic.10 With lower doses, and in 
combination therapy, the haematological 
adverse events occur less frequently. Anaemia 
at baseline should not preclude the use of 
Zidovudine in patients initiating ART in 
resource-limited settings.11
The following revised haemoglobin (Hb) 
and haematocrit (Hct) levels are based on 
recommendations published by Lawrie et al.12 
in 2009, in which the normal ranges for Hb 
were found to be: 13.4 - 17.5 g/dl in males and 
11.6 - 16.4 g/dl in females. Lower values may 
be accepted as normal in selected settings (e.g. 
evaluation during pregnancy or at sea level). 
There is significant variability in the definition 
of anaemia in relation to Hb level. Although 
anaemia may be strictly defined as a Hb level 
<13.4 g/dl for males and <11.6 g/dl in females, 
investigating all patients with Hb levels that 
approximate these values are both impractical 
and of questionable value in resource limited 
settings.
A baseline full blood count (FBC) with a 
differential count should be performed on 
all newly diagnosed HIV-positive patients. 
Clinicians are advised to monitor the patient’s 
Hb level regularly in accordance with local 
guidelines. All patients with anaemia should 
be investigated for the underlying cause(s) 
and treated appropriately. While reduced 
red blood cell (RBC) production frequently 
underlies HIV-related anaemia, it is important 
to exclude other causes e.g. haemolysis or 
blood loss.
The reticulocyte count and corrected 
reticulocyte production index (RPI) will guide 
one with regard to the underlying aetiology 
(e.g. decreased production or increased 
destruction). This discrimination is important 
as management differs accordingly. The 
reticulocyte count is a useful index of bone 
marrow function, and should increase in 
response to any blood loss (e.g. haemorrhage or 
haemolysis). Failure to increase appropriately 
may reflect a primary production problem 
that can affect multiple cell lines (e.g. aplastic 
anaemia) or be specific to one cell line (e.g. 
Parvovirus B19-related pure red cell aplasia 
(PRCA)). The reticulocyte count is normally 
0.6 - 1.83%,13 but different textbooks and 
laboratories use different reference ranges. 
With anaemia, the corrected reticulocyte 
count (cc) is adjusted for the lower Hct. 
A reticulocyte production index of 1 - 2% 
indicates an appropriate marrow production; 
3% or more indicates haemolysis; and levels 
<1% suggest reduced production.
Mean corpuscular volume (MCV) changes 
with age. From age 1 to 8 years, the lower limit 
of the MCV can be roughly calculated using 
the formula: age in years + 70 fl. In adults, 
MCV is typically 80 - 100 fl. An MCV less 
than this range suggests microcytosis, while 
greater levels suggest macrocytosis.
Fig. 1 provides a practical investigative 
approach to the causes of anaemia in the HIV 
positive patient.
Iron deficiency is the most common cause 
of microcytic anaemia. Iron deficiency is not 
a definitive diagnosis; rather, it reflects an 
underlying pathology that must be identified 
and treated appropriately and specifically. 
The mechanisms for iron deficiency include 
reduced intake (e.g. nutritional deficiency 
and inflammatory bowel disease) as well as 
increased loss (either acute haemorrhage 
or chronic, e.g. menorrhagia, helminthic 
infestation, gastrointestinal bleeding). Iron 
deficiency requires iron supplementation 
administered orally or parenterally. The latter 
may incur risk of, among others, anaphylaxis, 
and should only be reserved for severe cases 
of iron deficiency where oral supplementation 
is not tolerated (e.g. inflammatory bowel 
disorders, malabsorption). Patients should 
respond to iron replacement therapy within 
2 months if the underlying cause has been 
addressed. Failure to respond within this 
period should prompt review of initial 
diagnosis with attention to patient adherence. 
Adherence is a recognised problem of iron 
supplementation, given gastrointestinal 
side effects. Excessive iron therapy can be 
deleterious and should not be given as a 
routine supplement in the absence of a clinical 
indication.14
In proven iron deficiency, one should 
– especially in children – consider 
administration of an anti-helminthic agent, 
in conjunction with iron therapy, in view of 
the high prevalence of co-morbid helminthic 
infestation in low-resource settings. 
Helminthic infestation (e.g. hookworm) 
is known both to cause and exacerbate 
underlying iron deficiency.
Transfusion should not be a first line of 
intervention in iron deficiency; oral iron 
is generally effective in managing stable 
patients. Transfusion is reserved for patients 
with decompensated anaemia (e.g. patients 
with signs of hypoxia, angina, cerebrovascular 
compromise, heart failure). Transfusion 
with red cell concentrate (‘packed cells’) can 
ameliorate symptoms in these patients. Each 
unit of packed red cells contains (replaces) 
approximately 250 mg of iron.
Macrocytic anaemia is often attributed 
to deficiencies in Vitamin B12 (cobalamin) 
and/or folate. In stable patients with proven 
vitamin B12 deficiency (pernicious anaemia), 
the patient should be treated with injectable 
vitamin B12 for at least 3 days before starting 
folate therapy. This is essential to avoid 
permanent neurological complications. In all 
other cases, start supplementation with folate 
and vitamin B12. The response to vitamin B12 
occurs within 48 to 72 hours. Serum potassium 
levels can fall during initial therapy for severe 
Vitamin B12 or folate deficiencies owing to 
increased utilisation of potassium by new 
haematopoietic cells; potassium levels should 
be monitored during therapy, with potassium 
supplementation where indicated.15,16
Blood transfusion should be avoided as 
patients with macrocytic anaemia generally 
tolerate extremely low haemoglobin levels 
very well. Transfusion can lead to circulatory 
overload especially in critically ill patients 
who require stringent maintenance of fluid 
volume status. In severely symptomatic 
anaemic patients, a maximum of 1 - 2 units 
of red cell concentrate may be administering 
slowly (over 4 hours per unit), followed by 
intravenous furosemide (20 - 40 mg), or be 
given in an isovolemic manner (i.e. removing 
250 ml of the patient’s whole blood, which 
has a low haematocrit, and replacing with 
250 ml of packed RBCs, which has a high 
haematocrit).
Anaemia of chronic disease (ACD) is 
common in HIV; the mechanism is complex 
and is caused, in part, by the release of 
cytokines, resulting in iron blockade and 
dyserythropoiesis. In ACD, haemoglobin 





levels seldom drop below 7 g/dl. Additional 
causes should be considered if haemoglobin 
levels fall below 7 g/dl. ACD does not respond 
to haematinics and requires treatment of the 
underlying condition (e.g. ART in the setting 
of HIV). Where treatment is not possible and 
the patient remains symptomatic, judicious 
use of erythropoietin can be considered.17,18
Autoimmune haemolytic anaemia is more 
common in HIV-infected patients than in HIV-
negative patients. The direct anti-globulin test 
(DAT) (Coombs test) is positive in up to 20 
- 40% of HIV-positive patients;19 few patients, 
however, demonstrate signs of haemolysis.20 
The presence of a high reticulocyte count, 
unconjugated hyperbilirubinaemia, elevated 
LDH, spherocytes on the peripheral smear, and 
falling haemoglobin, suggests haemolysis and 
should prompt further investigation. Primary 
management of AIHA is similar to that of the 
HIV-negative patient (i.e. treatment of the 
underlying cause (e.g. ART), corticosteroids, 
IVIG, and immunosuppressive therapy).21 
These therapies generally require specialist 
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* Investigating all HIV+ patients with HB levels below the normal range is not possible in resource limited settings.
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Fig.1. Diagnostic algorithm for anaemia in HIV infection.
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input and/or support. AIHA can complicate 
compatibility testing and the rapid access 
to blood for transfusion. Red cell auto-
antibodies can mask clinically significant 
allo-antibodies that have developed owing to 
prior antigen exposure (e.g. pregnancy and/
or previous blood transfusion). In non-urgent 
cases, a full serological investigation should 
be done to resolve the specificity of the auto-
antibody as well as to exclude any co-existing 
allo-antibodies. Once an allo-antibody has 
been excluded, it is generally acceptable to 
administer red cell transfusions to patients 
whose DAT is positive and where the indirect 
anti-globulin test (IAT) phase of the cross-
match is also positive; a haemolytic transfusion 
reaction in these patients is unlikely.21 These 
patients do, however, warrant slow transfusion 
and careful monitoring.
Importantly, the reticulocyte count and 
peripheral smear must be requested before 
a transfusion, since the value of the count as 
well as the appearance of the peripheral blood 
morphology and the MCV may change after a 
transfusion and not truly reflect the patient’s 
haematological status.
Thrombocytopaenia
Thrombocytopaenia occurs commonly (often 
as one of the presenting symptoms), increases 
with disease progression, and is associated 
with shortened survival in HIV-positive 
patients.22-25 The most common cause of 
primary HIV-associated thrombocytopaenia 
is immune-mediated destruction.25 This is 
frequently attributed to high levels of auto-
antibodies directed against platelet-associated 
antigens. HIV can also infect megakaryocytes 
directly, given megakaryocyte expression of 
CD4 and CXCR4 receptors which are known 
docking points for HIV.25 Consequently, 
platelet production and lifespan are reduced 
in the HIV-positive patient. Additional causes 
of reduced platelet survival and decreased 
production are listed in Table 2.
As with anaemia, thrombocytopaenia 
is associated with a poor prognosis, 
while the treatment of the cause of the 
thrombocytopaenia confers improved 
survival.26-28 Most patients with a platelet 
count >30 x109/l do not require treatment 
but do warrant investigation to elucidate the 
underlying cause.
Patients do not generally bleed sponta-
neously at platelet counts >10 - 20x109/l. 
Prophylactic platelet transfusion is seldom 
indicated. Some exceptions include: 
prematurity or neonatal thrombocytopaenia; 
intracranial pathology or risk of intra-cranial 
haemorrhage; functional platelet disorders 
independent of platelet count. Therefore, 
platelet counts <100x109/l may warrant 
investigation as to the underlying cause 
with appropriate management, but do not 
necessarily require platelet transfusions in 
the absence of bleeding. A unit of platelet 
concentrate containing >3x1011 platelets 
usually results in an increment in the platelet 
count, in an adult, of ~ 30x109/l. In the absence 
of factors that shorten the lifespan of transfused 
platelets (such as fever, splenomegaly and/
or anti-platelet antibodies), the lifespan of 
transfused platelets is ~3 - 4 days.
Immune mediated 
thrombocytopaenias
Immune thrombocytopaenia (ITP) 
can occur at any stage of HIV but most 
commonly in early disease. Auto-antibodies 
directed against platelet antigens are readily 
found in most people with HIV, but they 
are not necessarily clinically significant. 
Laboratory confirmation of ITP is complex; 
consequently, ITP is a diagnosis of exclusion. 
First line therapy is oral prednisone (1 mg/
kg each day). Prednisone at this dosage 
does not appear to significantly affect viral 
replication; it may, however, promote Kaposi 
sarcoma growth.29 If there is no response to 
steroids after one week, prednisone dosage 
can be increased to 2 mg/kg per day. Patients 
should not receive high-dose steroids for 
more than 2 weeks without referring the 
patient to a specialist unit. Patients on 
steroids require proton pump inhibitor (PPI) 
or H2-receptor antagonist prophylaxis for the 
prevention of peptic ulcer disease related to 
steroid therapy. If the platelet count drops 
below 30x109/l, IVIg therapy, with or without 
steroids, should be considered (exception: 
patients with haemophilia or patients on 
anticoagulation therapy, where the lowest 
accepted platelet count is usually 50x109/l). 
Response to therapy should be monitored, 
and ART needs to be initiated or continued. 
A high index of suspicion of concomitant TB 
should be maintained. Tranexamic acid and 
progesterone should be considered in female 
ITP patients presenting with a platelet count 
<50x109/l and genito-urinary bleeding – 
remembering, though, that tranexamic acid 
in patients with haematuria may result in 
blood clots and urinary colic. It is prudent 
to give patients prophylactic pneumococcal 
vaccination in anticipation of potential need 
for splenectomy. It is recommended that 
refractory patients be referred to a tertiary 
unit for further management.
Table 2. Thrombocytopaenia and HIV infection



























Immune thrombocytopaenia (secondary – 
HIV associated)
Thrombotic thrombocytopenic purpura 
(TTP)
Disseminated intravascular coagulation 
(DIC)
Haemolytic uraemic syndrome (HUS)
Hypersplenism
   Infection
   Haemophagocytosis
Drugs
   Interferon
   Saquinavir
Secondary anti-phospholipid syndrome





Thrombotic thrombocytopaenic purpura 
(TTP) is a medical emergency with a high 
mortality rate. Despite being frequently 
encountered in HIV, the diagnosis is often 
missed. With timely and appropriate 
management, the prognosis is significantly 
improved. TTP should be considered 
in all patients presenting with signs of 
micro-angiopathic haemolytic anaemia, 
thrombocytopaenia, fever, renal and liver 
dysfunction, and fluctuating neurological 
signs. Where possible, patients should be 
referred urgently to a tertiary facility for 
further aggressive management. Therapeutic 
plasma exchange (TPE) is ideal as it allows 
large volume plasma transfusions. If TPE is 
not available, fresh frozen plasma (FFP) or 
cryo-poor plasma at ~30 ml/kg per day should 
be infused in divided doses. TTP associated 
with HIV has been shown to respond well 
to FFP infusion alone and is appropriate 
in resource-limited settings without TPE.5,30 
Prednisone therapy at 1 mg/kg per day is 
also recommended. Tranexamic acid should 
be avoided. Platelet transfusions are not 
routinely given to patients with TTP as 
they may potentiate thrombotic events and 
complicate monitoring therapeutic response.
Neutropaenia
The incidence of neutropaenia similarly 
increases with HIV disease progression.31,32 
The aetiology of neutropaenia is often multi-
factorial and attributable to conditions 





•	 Transfusion is only one element of the 
patient’s management.
•	 The decision to prescribe blood products 
should be based on individual patient 
needs, informed by best practice as well 
as the transfusing institution or national 
guidelines (e.g. Clinical Guidelines for the 
use of Blood Products in South Africa).33 
Blood should only be transfused when 
clinically indicated and where the benefits 
outweigh the recognised risks.
•	 Appropriate management of chronic 
anaemia through investigation and 
treatment of the underlying cause may help 
to reduce the need for blood transfusion.
•	 Blood loss should be minimised to reduce 
the need for transfusion.
•	 A patient with acute blood loss should 
receive effective resuscitation with 
intravenous replacement fluids, oxygen and 
immediate measures to stop further blood 
loss, while the need for transfusion is being 
assessed.
•	 An appropriately trained healthcare worker 
must monitor the transfused patient and 
respond immediately and appropriately if 
any adverse event occurs.
•	 To avoid wastage and unnecessary risk, 
the clinician should prescribe the 
minimum effective volume of blood and 
blood products necessary to stabilise the 
patient. Routine transfusion to predefined 
haemoglobin (Hb) levels should be avoided.
Blood should be transfused or discarded 
within 6 hours of breaking the seal on the 
blood bag to prevent risks associated with 
bacterial contamination.
Special considerations
Rate of transfusion. The rate of transfusion 
depends on the indication for the transfusion, 
patient’s co-morbidities and prior response to 
transfusion, if known. For example, those with 
acute haemorrhagic shock require rapid rates 
of transfusion as part of  urgent resuscitation 
management. In contrast, patients with 
longstanding chronic anaemia should not be 
transfused rapidly (rate should not exceed 
2 ml per minute), given adaptation to their 
longstanding anaemia where rapid transfusion 
can precipitate cardio-respiratory failure. 
Particular caution needs to be taken for patients 
at age extremes (e.g. neonates, children, and 
age ≥60) and those with co-morbid disease 
(e.g. renal and cardio-pulmonary disease). 
These patient groups are at particular risk of 
volume overload, also referred to as transfusion 
associated circulatory overload (TACO). 
Precautions to minimise the risk of volume 
overload include spacing of transfusions 
where possible, small volume infusion, and/
or low dose furosemide following transfusion 
(where not contraindicated).
Filters. Red blood cells, whole blood, FFP 
and cryoprecipitate must be administered 
through a standard blood administration set. 
These sets have 170 - 240 µm mesh filters to 
prevent the transfusion of clots or coagulation 
debris. The filter should be covered (‘primed’) 
with blood to ensure that the full filtering area 
is used. Platelets should be transfused with 
a platelet giving set (a standard filter may be 
used in an emergency). Standard filters incur 
significantly greater platelet loss owing to 
adhesion to the comparatively larger surface 
area, larger chamber and longer tubing. 
Administration sets should be changed:
•	 following reported transfusion reactions; 
this prevents further introduction of 
potentially harmful blood entering the 
patient. This is particularly important in 
the setting of suspected septic transfusion 
reactions where bacteria from the 
implicated unit can similarly contaminate 
the original administration set.
•	 between red cells and other blood products
•	 between red cell units of different ABO 
groups (e.g. group O and group A red cells 
administered consecutively)
•	 prior to infusing other fluids (e.g. Dextran, 
Ringers lactate)
•	 every 12 - 24 hours (or according to the 
package insert/instruction) in patients 
requiring on-going transfusion.
Temperature of the blood. Blood warmers 
are not indicated for routine blood transfusion; 
cold blood transfused at a slow rate is unlikely 
to adversely affect the patient. Selected 
indications for blood warming include:
•	 massive transfusion >50 ml/kg/hr
•	 infants transfused at >15 ml/kg/hr
•	 neonates receiving exchange transfusion or 
large volume transfusion
•	 patients with high titre cold haemagglutinins 
reactive in vitro at temperatures >30oC.
In these select settings, large volume or 
rapid infusion of cold blood can precipitate 
cardiac arrhythmias and impair haemostasis. 
Blood warmers should be designated only for 
transfusion use, and require a temperature-
monitoring device that has been properly 
maintained in line with the manufacturer’s 
instructions.
Improper or excessive warming can induce 
haemolysis of the red cells, with consequent 
renal failure and even death. Blood must 
never be placed in a microwave or oven. 
Rapid warming in a water bath is ineffective 
as only the outer cells are warmed and, at 
temperatures >37°C, may cause damage 
to these cells. Moreover, this practice risks 
bacterial contamination of the transfusion 
ports.
Patient identification. Near-miss or 
actual misdirected transfusions remains the 
greatest risk of a haemolytic reaction to any 
patient receiving a blood transfusion. It is 
the responsibility of each person involved 
in the transfusion of the patient to avoid 
identification errors. This begins with the 
prescribing doctor and extends to all staff 
involved in administering the transfusion. 
Patient identification should be repeated at 
every step of the transfusion process to ensure 
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that errors do not occur. Where possible, the 
patient should be positively identified in the 
presence of 2 staff members. The patient needs 
to state his or her name, which should be an 
identical match with that on the chart and with 
the name on the blood packs for transfusion. 
Where the patient is unable to state his or her 
name, confirm the identity by using at least 2 
or, if possible, 3 identification points, e.g. full 
name, hospital number, date of birth and/or 
identification number. Scrupulous attention to 
detail can help to prevent serious harm. Clerical 
error (i.e. through patient or blood product 
misidentification) is the foremost reason for 
severe haemolytic transfusion reactions.
Paediatric patients. Anaemia in paediatric 
patients is very common in Africa.34 In Ghana 
and Malawi, for example, more than 50% of 
children <5 years have a haemoglobin level <11 
g/dl, and 20 - 47% of those admitted to hospital, 
reportedly receive blood transfusions.35-37 
Furthermore, 6 - 13% of patients admitted with 
severe anaemia (Hb<5 g/dl) die – many before 
transfusion is possible. Anaemia in southern 
Africa disproportionately affects the young, 
given pervasive malnutrition, and helminthic 
and infectious diseases (specifically HIV and 
malaria, both endemic to southern Africa). 
This has a major adverse effect on childhood 
morbidity and mortality, particularly where 
resource constraints and the relatively high 
cost of blood transfusion limit availability of 
safe blood.
Both anaemia and thrombocytopaenia are 
common among South African HIV-positive 
children. Of those referred with cytopaenias, 
~35% are anaemic (Hb <11 g/dl), ~12.5% have 
thrombocytopaenia, ~35% have combined 
anaemia and thrombocytopaenia, and ~10% 
are pancytopenic.38 The need for blood 
transfusion places a significant burden on 
transfusion inventories and hospital budgets.
Critically ill paediatric patients and neonates 
have special transfusion requirements. 
Neonates specifically, require small-volume 
transfusions that are relatively fresh (collected 
within the previous 14 days) and, when 
feasible, leucodepleted and/or CMV-negative. 
Neonates are particularly susceptible to 
volume overload, and measures should be 
adopted to counteract the risk e.g. small-
volume and slow rates of transfusion. Given 
the risks of transfusion, both the decision to 
transfuse and the required volume should be 
carefully considered and individualised.39
In stable HIV-infected anaemic children, it 
is reasonable to consider a Hb <6 g/dl as the 
transfusion trigger.40,41 A threshold Hb of 7 - 8 
g/dl is recommended in haemodynamically 
stable, critically ill patients (e.g. trauma, 
intensive supportive care, or surgery).42-44 
Higher thresholds are required in premature 
infants and children who are actively 
bleeding.45 The recommended volume of 
transfusion is 10 ml/kg for red cell concentrate 
and, in severe malnutrition or heart failure, 
5 ml/kg. For each 1 g/dl rise in Hb desired, 
3 - 5 ml/kg are needed. A paediatric unit 
of red cell concentrate contains 60 - 80 ml 
of red cells, compared with an adult unit of 
approximately 265 ml red blood cells. The 
calculated transfusion volume needed should 
be rounded off to the nearest volume of bag 
available, to not waste this scarce resource.
Appropriate clinical use of plasma 
products.33 Plasma products produced 
by component processing laboratories at 
the blood service centres through physical 
separation techniques are referred to as 
plasma components. Products derived from 
large pools of plasma by chemico-physical 
processing techniques (fractionation) are 
referred to as plasma derivatives.
Fresh frozen plasma (FFP) refers to plasma 
that is separated from anticoagulated whole 
blood and frozen within 18 hours of donation. 
FFP contains all coagulation factors at 
normal physiological levels. The indications 
for transfusion of FFP are outlined in Table 
3 and are identical to those for HIV-negative 
patients. FFP should be transfused judiciously. 
In addition to infectious risk, it is associated 
with transfusion-related acute lung injury 
(TRALI), which has significant morbidity 
and mortality. Inappropriate uses of FFP 
include volume expansion and nutritional 
supplementation.
Cryoprecipitate is the cold insoluble 
fraction of FFP and contains Factor VIII and 
von Willebrand Factor (100 IU per unit), 
fibrinogen (150 - 250 mg per unit), fibronectin, 
and Factor XIII. It is indicated primarily 
for the treatment of hypofibrinogenaemia 
(acquired or congenital) as found mainly in 
DIC states. Owing to the relative low levels of 
Factor VIII and von Willebrand Factor, it is 
not indicated in von Willebrand ’s Disease or 
in Haemophillia A.
Freeze dried plasma (FDP) is produced 
from pooled fresh human plasma that has 
been subjected to a pathogen inactivation 
procedure that inactivates lipid-enveloped 
viruses. FDP has the same indications and 
dosage as FFP.
Intravenous immunoglobulin (IVIg) 
is prepared by a fractionation process 
which inactivates lipid-enveloped viruses. 
The two principal indications for IVIg 
are antibody replacement therapy and 
immunomodulation. In the setting of HIV, 
IVIg is primarily used in the management 
of ITP and PRCA.
Intramuscular hyperimmune immuno-
globulin is produced by a method of 
fractionation similar to that of intravenous 
preparations. Most preparations have a 
high titre of antibodies for passive immune 
prophylaxis against selected infections (e.g. 
chicken pox, hepatitis B, rabies etc).
Oncology patients. Independent of HIV 
status, the oncology population is a major 
user of blood and blood products. Certain 
malignancies are AIDS-defining conditions 
(e.g. high-grade B-cell non-Hodgkin’s 
lymphoma, Kaposi’s sarcoma and carcinoma 
of the cervix). However, HIV-positive patients 
are susceptible to the full range of malignancies 
encountered in HIV-negative patients, such as 
breast cancer, colorectal cancer etc. With the 
advent of HAART, as HIV-positive patients live 
Table 3. Clinical indications for FFP
Indications




Active or ongoing bleeding with abnormal coagulation tests
Replacement of inherited single factor deficiencies, where single factor concentrate is not 
available
Thrombotic thrombocytopaenic purpura
Reversal of warfarin with active bleeding where prothrombin complex concentrate (PCC) 
is not available
Vitamin K deficiency associated with active bleeding
Scoline apnoea





longer, they will be at risk of the same spectrum 
of malignancies as seen in negative individuals.
General transfusion principles apply to the 
HIV-positive oncology patient. The decision 
to transfuse should be individualised to the 
patient’s needs; this can be challenging in 
patients with uncertain outcomes. For example, 
transfusion in patients with poor expected 
short-term outcomes may be inappropriate if 
it is unlikely to change the outcome. However, 
transfusion has a role in palliative care where 
it can be used to maintain or improve quality 
of life in terminally ill patients. Adjunctive 
therapy with haematinics, erythropoietin and 
other alternatives to transfusion should be 
considered in patients who require active 
management of their anaemia.
Transfusion thresholds can differ to 
accommodate planned therapies. For 
example, radiotherapy requires a higher 
tissue oxygenation to be effective; therefore 
these patients require a higher haemoglobin 
level, and a target of 10 g/dl should be used. 
Similarly, maintenance of higher haemoglobin 
levels has been shown to improve radiotherapy 
outcomes in head and neck cancer.46
Surgical patients. Perioperative indications 
for blood transfusion are the same for both 
HIV-positive and -negative patients. However, 
HIV-positive patients are more likely to 
be anaemic and consequently more likely 
to require transfusion pre-operatively. All 
reasonable measures must be taken to treat 
and correct anaemia and its causes before 
surgery. Estimating transfusion needs and 
communicating with the hospital blood bank 
is especially important. Algorithms to help 
predict need for transfusion may be useful47 
but, in practice, if the patient presents at 
surgery with a haemoglobin level <7 - 8 
g/dl, and the predicted blood loss is >500 
ml, then perioperative transfusion should 
be anticipated and planned according to the 
patient’s condition.48
A study of Jehovah’s Witness patients 
undergoing surgery who refused transfusion 
noted that mortality in elective surgery 
depended on estimated blood loss rather 
than on preoperative haemoglobin levels. 
Furthermore, the study found that elective 
surgery could be performed safely in patients 
with a preoperative haemoglobin level as low 
as 6 g/dl if estimated blood loss was maintained 
below 500 ml.49 Other studies in Jehovah’s 
Witness patients have demonstrated a 
significant increase in mortality and morbidity 
in patients with a postoperative haemoglobin 
level <7 g/dl and 8 g/dl respectively.50
It has been shown that the risks of surgery and 
anaesthesia in HIV-positive patients is similar 
to that of surgery in immunocompromised 
or malnourished patients, with increased 
risk with disease progression.51 As for any 
patient, the preoperative physiological status 
(including an assessment of nutritional 
reserve) is considered the best predictor of 
surgical morbidity and mortality.52 HIV-
associated thrombocytopaenia can potentially 
increase the risk of bleeding, but regional 
anaesthesia is not contraindicated.52,53
Haemophiliac patients. In the late 1970s 
and early 1980s, patients with haemophilia 
(PWH) were infected with HIV through 
the use of contaminated blood products, 
specifically clotting factor concentrates, FFP 
and cryoprecipitate. This tragedy has since 
lead to a complete revision of transfusion 
practice, policy and procedures. With robust 
donor selection, sensitive laboratory testing 
and good manufacturing practice for the 
production of fractionated factor concentrates, 
the current risk of transfusion-transmitted 
HIV is very low. However, development of 
thrombocytopaenia, lymphadenopathy or 
splenomegaly in PWH still warrants testing 
for HIV infection.
PWH who are found to be HIV-positive can 
develop thrombocytopaenia consequent to 
their HIV disease. Therefore, the development 
of purpura or increased mucosal bleeding 
in an HIV-positive PWH may be due to 
thrombocytopaenia rather than factor 
deficiency. Investigation and identification of 
the cause is important: factor administration 
alone may not be sufficient, and therapy 
may need to be directed toward the HIV 
thrombocytopaenia (as a primary cause). 
Management is similar to that of patients 
without haemophilia, and includes steroids, 
platelet transfusions and, in the HIV-positive 
patients, the initiation of HAART.
Obstetric patients. Regarding blood 
transfusion, the management of HIV-
positive obstetric patients should not differ 
from that of HIV-negative obstetric patients. 
Transfusion should be used sparingly 
in obstetrics. Pregnancy may, however, be 
associated with sudden massive blood loss 
– obstetric haemorrhage remains the third 
most common cause of maternal mortality 
in South Africa.54 Hospital maternity sections 
frequently rank among the highest in terms of 
demand for blood and blood products, along 
with trauma and ICU.55
There is a high prevalence of underlying 
anaemia in pregnancy owing to various causes. 
This anaemia must be anticipated, recognised 
and treated to lessen the risk associated 
with blood loss at delivery and to lessen 
the requirements for transfusion. Specific 
physiological changes in the haematological 
system occur in pregnancy, including 
haemodilution (there is an increase in plasma 
volume by 45 - 50% that reaches a maximum 
at about 34 weeks’ gestation and exceeds the 
18 - 30% increase in the red cell mass).56 In the 
anaemic patient on oral haematinics, a static 
Hb may represent a response to the anaemia 
masked by haemodilution. Plasma volume 
increases more in multiple pregnancies.
The fetus must also be considered in 
terms of the potential effects of the anaemia. 
Folic acid deficiency (a cause of pregnancy-
related anaemia) has been associated with 
neural tube defects. Periconceptual folic acid 
supplementation is recommended.57
Pregnancy is also associated with specific 
disorders that affect the haematological 
system, increasing the need for transfusion. 
These include HELLP syndrome (haemolysis, 
elevated liver enzymes and low platelets) 
associated with pre-eclampsia/eclampsia and 
pregnancy-associated thrombocytopaenia.
Although these guidelines contain 
recommendations for complex investigations 
and discuss current blood product use, it is also 
recognised that a large proportion of pregnant 
patients in South Africa and elsewhere in 
Africa are cared for at primary care centres 
where only basic haematological investigation 
may be available. In parts of southern Africa, 
the available blood supply does not meet the 
clinical demand, and clinicians face a chronic 
shortage of blood. In all circumstances, much 
can be achieved by the prompt use of standard 
obstetric protocols to minimise blood loss. 
Where possible, the more complex patient 
who requires specialised antenatal or intra-
partum care should be transferred to better-
resourced settings.
The prevalence and cause of anaemia 
in pregnancy varies throughout Africa. In 
Malawi and Zimbabwe (and in the Limpopo 
and northern KwaZulu-Natal provinces of 
South Africa), for example, malaria and/or 
gastrointestinal parasite infection may be a 
cause of anaemia in addition to underlying 
nutritional deficiencies. Should a patient 
in such areas become infected with HIV, 
these underlying causes of anaemia will 
persist and require treatment in accordance 
with the principles mentioned before.58 
Anaemia should be identified, appropriately 
investigated, and treated early in pregnancy. 
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Other haematological complications such 
as bleeding tendencies and cardiac failure 
warrant urgent admission or referral to a 
secondary/tertiary centre. Routine obstetric 
assessment includes the gestational age, which 
indicates the time available to treat a low Hb. 
Risk factors for obstetric haemorrhage may 
indicate referral to a secondary/tertiary centre 
for delivery, where transfusion, if required, 
will be available.
According to the South African National 
Prevention of Mother to Child Transmission 
of HIV (PMTCT) Clinical Guidelines (2010),59 
all HIV-positive pregnant women should 
receive iron and folate supplementation. In 
South Africa, folate should be available at 
the treatment dose of 5 mg and not the 
prophylactic dose. In countries where folate 
fortification of food takes place, folate 
deficiency is rare. The recommended daily 
dosage for iron is 60/65 mg elemental iron 
in the 2nd trimester and 120 mg elemental 
iron, in divided doses, in the 3rd trimester. 
If there is intolerance, replacement can be 
deferred since, in the 1st trimester, oral iron 
may cause increased nausea and vomiting. 
If calcium is given antenatally, it must not 
be given at the same time as the iron, as it 
blocks absorption.60,61 There is an exception: 
Patients with a known haemolytic anaemia 
– e.g. thalassaemia or sickle cell anaemia 
(particularly from malaria-endemic areas) – 
should not be given iron routinely.
Anaemia must be recognised and managed 
promptly before the time of likely delivery. 
The time intervals for assessment of response 
are therefore shorter than in the non-pregnant 
patient. A review after only 3 months is not 
appropriate.
1. For treatment, dosage: 200 - 250 mg 
elemental iron daily in divided doses, i.e. 
one tablet of iron sulphate or iron fumarate 3 
times daily. If vitamin C is available, it should 
be given with iron, also in divided doses.61 
Iron taken with food increases tolerance.
2. There is an increased absorption of iron 
in pregnancy. If the anaemia is a result of 
iron deficiency, an Hb increase of up to 0.7 
g/dl per week may result. The lower the 
starting Hb, the more rapid the anticipated 
response.
2.1   With an inadequate (<0.5 mg/dl 
per week) or absent response, a full 
blood count (FBC) and reticulocyte 
production index (RPI) should be 
performed. The RPI is frequently >2 
in the early response to iron deficiency 
anaemia in pregnancy.
2.2   The FBC may direct further investigation 
of the anaemia as mentioned above.
2.3   In iron deficiency anaemia responding 
to iron but with a delayed Hb response, 
the red cell distribution width (RDW) 
may also increase, usually to >20%. 
The increase in RDW is not valuable 
if a recent transfusion or drugs have 
been given that cause macrocytosis e.g. 
AZT62 causing an artificial increase in 
RDW.
2.4   If the MCV is high (>110 fl), Vitamin 
B12 deficiency, though rare, should be 
considered, especially if there is oral 
ulceration or neurological symptoms.
Intravenous iron is only indicated, remote 
from term, if iron deficiency anaemia, 
proven on FBC and iron studies, is associated 
with intolerance of oral iron or there is no 
improvement of the anaemia despite apparent 
compliance.63 Intravenous iron should only 
be given where there is no other reason for 
immediate transfusion.
According to the National PMTCT 
Guidelines (2010), the newly diagnosed HIV-
positive pregnant patient who has a CD4 
count >350 cells/mm3 or WHO Staging 1 or 
2 should, after 14 weeks’ gestation, commence 
Zidovudine (AZT), if consenting. If CD4 
count <350 cells/mm3, or WHO Stage 3 or 4, 
full ART should be offered.59 AZT is associated 
with macrocytosis,62 but rarely associated with 
severe anaemia as a result of a pure red cell 
aplasia.64 If there is adequate time remaining 
in the pregnancy, patients who are treatment-
naïve, do not qualify for full ART, and have 
an Hb <10g/dl, should receive a full course 
of haematinics and their response observed. 
Their response should be re-assessed after 
2 weeks and, if there is a response, AZT 
be commenced. If the patient’s Hb is <8g/
dl, the South African PMTCT Guidelines 
suggest withholding AZT.59 If, however, there 
is a rapid response of the anaemia to iron and 
folate, AZT can be given. If the Hb is <8g/
dl and there is no response to haematinics, 
further investigation is warranted. In certain 
patients, there may be a case for considering 
full ART. These include cases where delivery 
is approaching and where the Hb remains 
low or is falling. Patients with a falling 
Hb on AZT (or AZT-containing regimen) 
should be investigated for other causes of 
anaemia, usually nutritional or infective, but 
autoimmune haemolytic anaemia should 
also be considered. Haematinics should 
be commenced if not yet initiated and the 
patient examined and investigated further 
for additional underlying pathology. If a pure 
red cell aplasia is confirmed, AZT should 
be stopped. In such cases, patients usually 
respond within a week. Blood transfusion may 
be required if the patient is symptomatic or if 
the Hb falls below 6g/dl with no response to 
treatment.
Many patients tolerate very low levels of 
Hb (5 - 6 g/dl). If there are no medical or 
obstetric complications, and it is early in 
pregnancy (<34 weeks), oral replacement with 
haematinics should be used and the patient 
reassessed after 1 - 2 weeks. Where patients 
are in cardiac failure, have worsening anaemia 
with no response to haematinics, or where 
delivery is imminent, transfusion should be 
considered. Transfuse one unit of red cell 
concentrate and reassess. There is no need to 
transfuse if the Hb >7 g/dl and there are no 
obstetric complications. A higher Hb (>8 g/dl) 
should be targeted in patients at increased risk 
of obstetric haemorrhage, e.g. previous PPH, 
multiple pregnancy and placenta previa (where 
a Hb >9g/dl should be targeted).
Routine obstetric intervention may 
prevent transfusion. Appropriate 
observation is critical. Timely caesarean 
section for antepartum haemorrhage, 
controlled delivery of the placenta in vaginal 
delivery, and the recognition and treatment 
of uterine atony may prevent the need for 
transfusion. If a transfusion is not to be given 
to a patient in whom the peripartum loss 
has been considerable (>500 ml in normal 
delivery, >1000 ml in caesarean section), 
the cause of bleeding must be controlled 
and the condition of the patient considered. 
Close observation is essential; any further 
blood loss must be accurately recorded 
and action taken if necessary. Blood loss is 
frequently underestimated.63 In patients with 
physiological compromise (both HIV-negative 
or -positive), transfusion should be considered 
earlier than in otherwise healthy counterparts.
If blood products are required and not 
available at the point of care, the patient 
should be transferred to a unit with access 
to a blood bank as soon as possible. The 
patient should be oxygenated, kept warm, 
with adequate intravenous (IV) support and 
with adequate measures to control further 
haemorrhage.
There is no need to give blood to reach 
a particular Hb level. Transfusion practice 
depends on the availability and proximity of 
blood products in the case of an emergency; 
the American and British Anaesthetic Task 
Forces in Obstetrics recommend neither 





routine type and screen, nor crossmatch 
of patients who undergo a routine normal 
delivery or routine caesarean section if these 
services are readily available.63,65 Despite these 
recommendations, patients at risk for greater 
than average blood loss (e.g. caesarean 
section for placenta previa) should have 
blood crossmatched and should, wherever 
possible, give birth in a place where further 
blood products are readily available.54
Malaria. The risk of severe malaria appears 
to be greater in HIV-positive (non-immune) 
patients than in HIV-negative patients.66 
In addition, HIV-positive patients are at a 
significantly higher risk of developing severe 
anaemia. Pregnant women co-infected 
with HIV and malaria are at greater risk of 
complicated disease than women with either 
malaria or HIV infection alone. Peripartum 
complications include severe anaemia,67 thereby 
increasing the need for blood transfusion.
Severely anaemic patients may benefit from 
transfusion early in the course of acute malaria 
but, once stable and in process of recovery, the 
benefit of transfusion68 is limited. However, 
persistent worsening anaemia is a recognised 
complication in the weeks following clearance 
of parasitemia.69 Clinicians should therefore 
monitor HIV-positive patients for at least 
3 months following malaria treatment. 
Paediatric patients are at greatest risk. One 
study of HIV-1 and Plasmodium falciparum 
co-infected children aged 3 - 36 months 
demonstrated significantly worse anaemia 
(Hb <6.0 g/dl) and a nearly 10 times greater 
mortality within 3 months post treatment, 
compared with an HIV-negative cohort.70
HIV-malaria co-infected patients are 
particularly prone to invasive bacterial 
infection (IBI); this underscores the need 
for good transfusion practice and vigilance 
against bacterial contamination.71 Improper 
handling of blood and blood products 
further increases the risk of Gram-positive 
bacteraemia. Broad-spectrum antibiotics 
(such as a third generation cephalosporin) 
should be routinely administered to HIV-
malaria co-infected patients with severe 
malaria, to provide cover against both 
Gram-positive and Gram-negative bacteria; 
this should be instituted from the time of 
admission.72 Aggressive initial management 
of malaria is essential. Blood transfusion has 
a role in management, but should not delay 
initiation of anti-malarial therapy.
Haemoglobinopathies. There is no 
evidence to suggest that patients with 
haemoglobinopathies who are HIV-positive 
should be managed differently to those who 
are HIV-negative.
Massive transfusions. The principles of 
management of patients requiring massive 
blood transfusion are the same for HIV-
positive and HIV-negative patients.
Leukodepleted blood. The routine use of 
leukodepleted blood in HIV-positive patients 
is not recommended. Even though HIV/
AIDS patients are immunosuppressed, there 
is no substantive data supporting improved 
outcomes in patients who routinely receive 
leukodepleted blood components. Currently, 
the indications for the transfusion of 
leukodepleted blood products are the same for 
HIV-positive and HIV-negative patients. While 
the use of leukodepleted blood products may 
reduce the risk of transmission of leucocyte-
associated pathogens such as CMV and HTLV, 
the Viral Activation Transfusion Study (VATS) 
demonstrated no clinical benefit for HIV-
positive persons, who received white-blood-
cell-reduced transfusions.73-75 The indications 
for use of leukodepleted products include:
•	 prevention of alloimmunisation:
•	 patients on chronic transfusion regimens, 
such as aplastic anaemia or sickle cell 
anaemia
•	 organ and stem cell transplant patients
•	 haem-oncology patients
•	 patients at risk for CMV infection such as:
•	 transplant patients receiving 
immunosuppressant drugs
•	 infants <1 year old
•	 prevention of febrile non-haemolytic 
transfusion reactions
•	 other
•	 patients undergoing cardiac surgery.
Note: Where indicated and if available, 
prestorage leukodepleted products obtained 
from blood services are preferable to bedside 
leukodepletion; prestorage leukodepletion 
removes leucocytes prior to release of 
cytokines, which are responsible for adverse 
effects such as febrile non-haemolytic 
reactions.
Random-donor platelet concentrates 
are prepared from buffy coats and are 
not usually leukodepleted. Single donor 
(apheresis) platelet concentrates are routinely 
leukodepleted; the indications for this product 
are similar to those mentioned above for 
leukodepleted products.
Irradiated blood products. HIV-positive 
patients do not routinely require blood 
products to be irradiated. Blood products are 
irradiated to prevent transfusion-associated 
graft v. host disease (TA-GvHD). It has 
been postulated that, in patients with HIV 
infection, depletion of CD4 cells increases 
the number of donor cells needed to induce 
TA-GvHD. In HIV and AIDS, there has to 
date only been one reported case of TA-GvHD 
despite widespread use of blood transfusions 
in patients with profound HIV-associated 
immune suppression. The indications for 
irradiated blood products are the same for 
HIV-positive as for HIV-negative patients. 
Specific indications for irradiation include:
•	 blood donations from blood relatives
•	 HLA-matched platelet concentrates





haematological disorders) receiving 
Fludarabine therapy.
Note: Please refer to the Clinical Guidelines 
for the use of Blood Products in South Africa 




Blood conservation (restrictive transfusion 
practice) is clinically effective in most patient 
subsets. In particular, the TRICC study76 
showed that restrictive transfusion practice 
applied to critically ill adult patients was at 
least as effective and potentially superior to 
that of liberal transfusion practice in terms of 
lower morbidity and mortality.76 This was also 
shown in a major randomised control trial 
(PICU study) of stable, critically ill children.43
Low-cost and relatively simple preventative 
measures can be employed to minimise blood 
use. One example is that of judicious screening 
for anaemia with early intervention. All 
cases of clinically significant anaemia should 
be investigated, and the underlying cause 
addressed and appropriately managed. Early 
intervention is particularly important for 
surgical candidates where timely management 
of anaemia can help to minimise periopertaive 
transfusion.
Clinicians should employ alternatives to 
blood transfusion wherever appropriate e.g. 
haematinic therapy in chronic anaemia or the 
use of crystalloids/colloids to restore blood 
volume in resuscitation. Where indicated and 
where available, erythropoietin is another 
measure to be considered in patients refractory 
to standard therapy.6,9,77 Erythropoietin has 
been shown to benefit HIV-positive patients. In 
the critical care setting, excessive phlebotomy 
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can exacerbate underlying anaemia; this 
can be avoided through considered testing, 
confined to that which directly influences 
patient management.
Good surgical and anaesthetic techniques, 
with particular attention to haemostasis 
and keeping patients warm, are essential 
transfusion conservation principles. Suitable 
alternatives or adjuncts to transfusion should 
be considered, e.g. anti-fibrinolytics and 
fibrin sealants. Bleeding, when it occurs, 
should be managed aggressively, avoiding a 
passive watch-and-wait approach. The use 
of medication that can impede haemostasis 
(e.g. anticoagulants, anti-platelet agents and 
non-steroidal anti-inflammatories) should be 
prescribed cautiously in the chronic patient at 
risk for bleeding, and stopped in the bleeding 
patient. The latter may require specific reversal 
of anticoagulation if bleeding does not stop 
with conservative management.
Pre-surgical autologous blood donation 
obtained from HIV-positive donors is not 
routinely available and should not be accepted. 
HIV-infected blood products pose significant 
risk, both to blood service staff as well as 
to other patients. Risk to other patients can 
occur through administrative or clerical error 
resulting in mis-transfusion (unintentional 
transfusion to the incorrect recipient).
Finally: acute normovolemic haemodilution 
and cell salvage are two intraoperative blood 
conservation techniques that can be used 
in HIV-positive surgical patients. These 
techniques should be considered particularly 
where significant blood loss is anticipated.
Lookback programmes
The Blood Service’s Transfusion Transmissible 
Infection (TTI) Lookback Programme aims to 
trace all patients who are identified as recipients 
of blood from donors who test positive for 
a transfusion-transmissible infection on 
a subsequent blood donation, where the 
initial (index) donation might possibly have 
been donated in a window period. In such a 
‘donor-triggered’ lookback investigation, the 
recipient/s of the previous TTI negative units 
is/are identified and their treating doctor 
notified. As far as possible, the patient must be 
recalled, counselled and tested for the relevant 
viral marker, and the result reported to the 
blood service. Despite diligent donor selection 
and laboratory screening, suspicion may arise 
that a patient might have been infected with 
HIV, HBV or HCV through blood transfusion. 
In such instances, the attending clinician 
should contact the blood service promptly 
to initiate a ‘recipient-triggered’ lookback 
investigation, a formal procedure designed to 
trace and confirm the status of the implicated 
blood donor(s).
Haemovigilance programme
Haemovigilance is the process through which 
information related to the transfusion of 
blood and blood products is monitored and 
centrally reported. It is a system to detect, 
gather and analyse information on untoward 
and unexpected effects of the transfusion of 
blood and blood products. Such programmes 
aim to improve blood systems and blood 
safety through the early detection and 
comprehensive reporting of untoward effects 
of blood transfusion e.g. transfusion reactions, 
transfusion-transmitted infections, etc. Ideally, 
a haemovigilance programme is integrated 
into blood transfusion practice to maximise 
the safety of not only the blood supply, but 
also all aspects of laboratory and clinical blood 
transfusion practice. In some countries such 
as Namibia and South Africa, data reported to 
the National Haemovigilance Programme are 
analysed and the results published in an Annual 
Haemovigilance Report. It is important that 
medical practitioners who transfuse blood and 
blood products report all adverse transfusion 
events to the blood service.
Laboratory testing of 
donated blood
Serological tests are performed on every blood 
donation to determine the donor’s ABO group 
and Rh type and to detect irregular blood 
group antibodies. Every blood donation is 
tested for HIV, hepatitis B, hepatitis C and 
syphilis, using serological techniques. Nucleic 
acid testing (NAT) is used in combination 
with serological testing in a few well-resourced 
African countries. Clinicians should consider 
the following options when ordering blood for 
their patients:
•	 Type and screen. The clinician should 
select this option if their patient has a 
low probability of needing a transfusion 
or in, for example, certain elective surgical 
procedures where the extent of blood loss 
is unpredictable. The blood specimen 
submitted to the blood bank will be tested 
to determine the patient’s ABO group and 
Rh type and will be tested to ensure that 
the patient does not have irregular blood 
group antibodies (a ‘rare blood type’) that 
could delay finding compatible blood. The 
specimen will be held for approximately 
96 hours, depending on blood bank 
policy. Blood will only be crossmatched 
when requested by the attending doctor. 
The ‘type and screen’ expedites cross-
matching and dispatch of blood from the 
blood bank should transfusion be required. 
If irregular antibodies are detected, the 
requesting doctor will be notified. The 
presence of irregular antibodies can delay 
procurement of compatible blood, and 
patient management needs to be changed 
accordingly. This could, for instance, 
necessitate delaying surgery.
•	 A full crossmatch refers to full compatibility 
testing between a patient’s blood sample 
(intended recipient) and a given donor (unit 
of blood). This includes the type and screen 
as described above as well as confirmatory 
blood grouping on the intended donor 
unit. In addition, the patient’s serum is 
‘crossmatched’ with the red blood cells of the 
donor to ensure serological compatibility. 
Incompatibility between patient and donor 
is reflected by in vitro agglutination.
•	 In contrast, an emergency crossmatch 
refers to partial compatibility testing, given 
the urgent need to transfuse. Blood is issued 
after performing the ABO group, Rh type 
and antibody screen only. Further testing 
is completed after the unit has been issued.
Providing sufficient clinical detail, 
including the HIV status of the recipient, to 
the hospital blood bank staff, will expedite 
the crossmatching process and the timely 
availability of compatible blood. The direct 
antiglobulin test (DAT) is, for example, 
positive in up to 40% of HIV-positive patients. 
This will manifest as a positive crossmatch. 
Knowing the patient’s HIV status will therefore 
assist the blood bank’s medical and technical 
staff in interpreting the compatibility test 





Evaluation of benefits and risks of transfusions 
should precede the decision to transfuse. All 
blood products carry risk of adverse effects. 
These include transfusion reactions, transfusion 
transmissible infections, alloimmunisation 
and immune modulation. The attending 
doctor must be familiar with best practice 
recommendations regarding transfusion 
practice, and is also responsible for obtaining 
and documenting informed consent.
Transfusion reactions are the most common 
hazard of blood transfusion, occurring with 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































variable frequency depending on the type of reaction. 
Transfusion reactions fall broadly into the following 
categories:
•	 haemolytic – acute




•	 reactions due to bacterial contamination
•	 reactions due to ‘citrate toxicity’
•	 reactions due to circulatory overload (TACO)
•	 transfusion-associated acute lung injury (TRALI)
•	 transfusion-associated graft versus host disease 
(TA-GvHD).














If a transfusion reaction is suspected, the 
transfusion must be stopped immediately pending 
further evaluation. The administration set must be 
changed and venous access should be maintained 
with normal saline unless it is a simple urticarial 
reaction. If the latter is the case, the transfusion 
can continue with symptoms or after use of an 
antihistamine (such as diphenhydramine 12.5 - 25mg 
for an adult patient).
The following additional steps should be taken:
•	 Both a member of the medical staff as well as the 
blood bank must be contacted immediately.
•	 The medical management of the transfusion reaction 
will depend on the type and severity of the reaction.
•	 The patient’s temperature, pulse, respirations and 
blood pressure must be recorded.
•	 All clerical and identity checks must be repeated to 
ensure that the correct blood product was transfused 
to the intended patient. Clerical error is the foremost 
reason for major acute haemolytic transfusion 
reaction, i.e. blood given to the wrong patient.
•	 If a case of misdirected transfusion is noted, 
immediate steps must be taken to locate the units 
originally intended for the patient, as they may be in 
the process of being transfused to another incorrect 
patient.
•	 Send a fresh blood specimen for compatibility 
testing to the blood bank.
•	 All empty and non-transfused blood units should be 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































An HIV-infected patient doesn’t warrant 
transfusion as the prognosis is poor anyway
Anecdotal reports of patients dying 
following transfusion led to the unjustifiable 
practice of withholding blood transfusion 
from HIV-positive patients. At the start of 
the HIV pandemic, patients presented with 
advanced disease and generally had little 
prospect of effective management. Today, 
with highly effective ART and prophylaxis, 
HIV is a chronic manageable disease with an 
excellent outcome. Transfusion best practice 
and a rational approach to the management 
of anaemia apply, independent of HIV status.
Moribund HIV+ patients require rapid 
correction of their anaemia
Again, best transfusion practice applies to 
the HIV-positive patient. Rapid correction 
of chronic anaemia increases the risk of 
transfusion-associated circulatory overload 
(TACO) and cardiac decompensation as 
would be encountered in any patient with 
severe chronic anaemia (see section on 
transfusion rates). HIV-positive patients with 
acute haemorrhage may require resuscitation 
and rapid transfusion, similarly to HIV-
negative patients.
If a patient needs only one unit of blood, he/
she does not need blood at all
The indication for transfusion is based 
on clinical symptoms and signs, and not on 
laboratory indices. Patients should be evaluated 
after each unit transfused. A single unit 
transfusion, in the right circumstances, may 
be sufficient to stabilise the patient. ‘Topping 
up’ the patient with additional blood after the 
indication for transfusion has been addressed, 
may confer additional unnecessary risk.
Disclaimer
Specific recommendations provided in this 
document are intended only as a guide to 
clinical therapy, based on expert consensus and 
best current evidence. Treatment decisions for 
patients should be made by their responsible 
clinicians, with due consideration for individual 
circumstances. The most current peer-reviewed 
literature, reference text books and local 
guidelines should always be consulted.
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The use of blood and blood products raises 
two broad categories of legal and human 
rights considerations: the rights of donors 
and the rights of recipients. Much of the 
debate regarding blood, blood products and 
HIV has historically focused on the rights of 
people to be protected from infection; very 
little focus has been placed on the rights of 
people living with HIV insofar as access to 
blood and blood products is concerned. 
This appendix expands on both categories 
of rights bearers – including the legal 
requirements of informed consent – as well 
as the issue of confidentiality as it relates 
to the communication of information on a 
patient’s HIV status.
Informed consent
South African law has recognised the concept 
of informed consent for many years.1,2, The 
right to informed consent has been fleshed 
out by way of case law,3 regulatory council 
guidelines,4 the Patients’ Rights Charter, 
and legislation.5 In particular, the National 
Health Act 61 of 2003 (NHA) has codified 
the law on informed consent and defines 
it as consent for the provision of a specific 
health service; the Act further stipulates that 
informed consent may only be provided by 
a person with legal capacity to do so, and 
that the person providing consent has been 
adequately informed.6
The law on informed consent is based on 
the notion that a patient – referred to in the 
NHA as a user – has the right to participate 
in any decision affecting his or her personal 
health and treatment.7 If, however, the 
circumstances prevent the user from making 
the decision himself or herself, the NHA 
provides guidance on how to proceed.8
Confidentiality
The communication of any information 
pertaining to a patient’s HIV status, 
whether positive or negative, is subject to 
the confidentiality provisions in the NHA.9 
Section 14 of that statute makes it clear that 
‘[a]ll information concerning a user, including 
information relating to his or her health status 
… is confidential.’ This guarantee is subject 
to the provisions of Section 15, which deals 
with access to health records. Simply put, 
Section 15(1) ensures that the guarantee of 
confidentiality should not stand in the way 
of running an efficient and effective blood 
service, including the appropriate handling of 
blood and blood products.
The rights of donors
In considering the rights of donors, two key 
questions arise: (i) Is there a right to donate 
blood?; and (ii) can blood services be used as 
a testing facility to determine an individual’s 
HIV status?
Is there a right to donate blood?
There is no right to donate blood. On the 
contrary, blood services are constitutionally 
obliged to take all reasonable steps to ensure 
a safe supply of blood and blood products. 
By necessity, this implies refusal to accept 
as donors those at high risk of carrying a 
transfusion-transmissible pathogen (such 
as HIV). However, the manner in which 
donors are treated may not result in the 
violation of fundamental constitutional 
rights and values. The need to protect public 
health cannot be done in a manner that 
unreasonably and unjustifiably limits rights. 
If it did, potential donors would have legal 
recourse to vindicate their rights.
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Can blood services be used as a 
testing site to test for HIV?
While potential donors should be 
discouraged from using blood donation 
services for the purpose of establishing their 
HIV status, there is nothing in the law that 
can be used to prevent this from happening. 
Both donor education and evidence-
based self-exclusion questionnaires serve 
as appropriate means to discourage and 
defer those at risk of HIV infection from 
donating blood. Provision of alternative 
HIV counselling and testing services also 
help to prevent the blood collection centre 
from being used as a default testing site. This 
relies on the premise that alternative testing 
services, of high quality, rendered in a non-
discriminatory way, are available outside of 
HIV-specific service points and are either 
free or affordable at point of delivery.
The rights of recipients
In considering the rights of recipients, two 
key issues arise: (i) the right to have access to 
safe blood and blood products; and (ii) the 
rights of terminally ill patients.
Right to have access to blood and 
blood products.
The right to have access to health services, 
which includes access to blood and blood 
products, is guaranteed in Section 27 of the 
Constitution. The central issue is whether 
access to blood and blood products can be 
denied solely on the basis of HIV status. 
This raises concerns of health rights as 
outlined in Section 27; it also breeches the 
constitutional guarantee of equality and 
protection against unfair discrimination. 
In this regard, two Constitutional Court 
decisions are relevant.10,11, Read together, the 
cases are clear: given that HIV infection is 
a chronic manageable condition for those 
with access to appropriate treatment and 
care, it would not be reasonable to limit 
access on the basis of HIV status alone.12
The right of access to safe and adequate 
blood and blood products obligates blood 
services to take all reasonable measures 
to ensure that such products are indeed 
available and safe for use; such measures do 
not require a blood service that is 100% safe, 
as the technology to ensure this does not 
exist. Where people have been exposed to 
unsafe blood and/or blood products despite 
blood services having acted reasonably, 
the latter cannot be held liable for any 
resultant harm. On the other hand, donors 
who have acted unreasonably – such as 
by misrepresenting their actual risk of 
infection in self-exclusion questionnaires 
– may indeed be sued for damages.13 In 
addition to civil liability, such a donor may 
also be criminally liable.
Rights of terminally ill patients.
The right to have access to health care 
services does not impose an obligation on 
the state – and those who provide public 
services – to ensure that everyone receives 
every health service they need. Instead, it is 
an obligation to ‘take reasonable legislative 
and other measures, within … available 
resources, to achieve the progressive 
realisation of [the right]’.14 This was made 
clear in Soobramoney v Minister of Health, 
KwaZulu-Natal.15 In its judgment on Mr 
Soobramoney’s appeal, the Constitutional 
Court adjudicated the claim on the basis of 
the State’s positive obligations under Section 
26(2), holding that the guidelines according 
to which access was limited were reasonable 
and had been applied ‘fairly and rationally’.16 
In the result, the State had complied with its 
Section 27(2) obligations.
The primary responsibilities of the 
physician are to assist the patient in 
maintaining an optimal quality of life by 
controlling symptoms and addressing 
psychosocial needs, as well as enabling the 
patient to die with dignity and in comfort.17 
It is considered ethically justifiable to 
discontinue life-sustaining treatment if the 
patient has the ability to make that decision, 
fully understands its consequences, and 
states that they no longer wish to continue 
treatment. A decision to withhold or 
withdraw life-prolonging treatment should 
be only be made by the senior clinician in 
charge of a patient’s care, informed by the 
patient’s views or those closest to him or 
her.18
There may be circumstances when 
withholding treatment, even if it is not 
requested by the patient, may be permissible. 
This may apply, for example, in cases akin to 
that of Soobramoney. Ordinarily, it would not 
be justifiable to discontinue life-sustaining 
treatment for cost reasons alone. That 
said, there may be cases in which the costs 
expended on one terminally ill patient could 
be better used on another patient with an 
improved outlook.19 In such circumstances, 
a health care facility may have the right to 
limit access to life-sustaining interventions, 
provided that such a limitation is based 
on reasonable national admission criteria 
developed by expert professional bodies, 
such as the HPCSA.20
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